Alumis (ALMS) is a clinical-stage TYK2 inhibitor company, $2.9B market cap, pre-revenue. The Q1 2026 10-Q filed May 14 is procedurally important — it confirms the NDA path and discloses a strategic review of the lonigutamab program inherited from the May 2025 ACELYRIN merger — but most of the investable signal is in adjacent filings and cross-ticker reads. We're surfacing now because the entry math has become specific.

What the filing says

The lead asset, envudeucitinib ("envu"), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, is on track for H2 2026 NDA submission. Phase 3 ONWARD1/ONWARD2 positive topline was reported in a March 30, 2026 8-K. Cash position is comfortable: $569.5M in liquid assets at quarter-end, $87M quarterly operating burn (≈6.5 quarters of runway), $300M ATM undrawn, no debt, no going concern. The January 2026 follow-on at $17/share raised $324M net; three directors and Foresite Capital participated for $24M combined, with Director Akkaraju adding another $7.6M in open-market purchases Nov-Dec 2025.

Post-quarter, management completed a strategic review of lonigutamab (anti-IGF-1R for thyroid eye disease) and announced it is exploring strategic alternatives. The $51M IPR&D intangible carried from the ACELYRIN deal is at impairment risk in Q2 2026. The Pierre Fabre license carries up to $490.5M in retained milestone/royalty obligations; ALMS can terminate on nine months' notice. The Climb Bio litigation contests up to $157.5M in lonigutamab-adjacent milestone receivables.

The revenue line dropped 90% YoY ($17.4M → $1.7M). This is a timing artifact — Q1 2025 included a one-time Kaken license recognition. Q1 2026 is pure development services.

What the market thinks

Stock $22.87, +307% trailing 12 months. Ten of eleven covering analysts bullish with mean target $39.70 (+73% upside). HC Wainwright downgraded to Neutral at $25 on the filing day; Wells Fargo and Guggenheim reiterated/raised same day at $51 and $34. Short interest is 16.2% of float, 7.4 days to cover.

Our scenario authors expected return of +30% over 540 days from $22.87 (E[Price] $29.78). Reverse-solving the market price two ways: either market-implied P(approval) is ≈44% (versus our 80%), or the market is pricing the success-case outcome at $25 versus our $36. Both readings imply roughly the same pricing gap.

Why the gap exists

The bull thesis is consensus-confirmed; the differentiation is in commercial trajectory, where it is not. ONWARD efficacy approaches biologic class — PASI 90 of 53-60% (roughly 2x Sotyktu's 27-36%), PASI 100 at Week 24 hitting 39-41% (approaching Skyrizi's 43%). BMY Sotyktu Q1 2026 global sales accelerated to +20% YoY from +3% in Q4 2025, confirming oral TYK2 demand is expanding, not commoditizing. JNJ's icotrokinra (approved May 2026) is an oral IL-23R peptide with PASI 100 of 27% Week 16 — weaker data, different mechanism, doesn't crowd the TYK2 category.

The doorway state is the 16.2% short interest against ten bullish analysts. Shorts are not betting against approval — base rates put that around 85-90% post-positive-Phase-3. They are pricing approved-restricted outcomes: BID dosing creates payer friction versus Sotyktu's QD; potential REMS or narrower label; slow launch curve versus a Street model anchored on Sotyktu trajectory. Analysts are sizing on data quality. The HC Wainwright filing-day downgrade likely reflects similar concerns; the specific note has not been read.

The ACELYRIN merger reads as the third instance of a balance-sheet-arbitrage biotech merger pattern (alongside KLRS-AlloVir and LAB). In these structures, target program disposition is the expected outcome, not deterioration. The lonigutamab "strategic alternatives" disclosure is the completion of the original thesis.

Entry and timing

At current $22.87, post-XBI-hedge α/σ is roughly 0.25-0.35 — marginal. A $18-19 retest (aligning with the $17 insider cost basis) lifts the Sharpe to 0.50-0.70 and widens margin of safety enough to pass a μ̂ − 1.5×SE significance test. The NDA catalyst carries meaningful XBI correlation; sector beta contributes noise to an otherwise idio-dominant thesis.

Timeline: NDA submission Aug-Dec 2026; FDA acceptance letter ≈60 days later (+10-15% typical bump); LUMUS SLE topline Q3 2026 (binary, +25%/-10% asymmetric); potential AdCom Q2-Q3 2027; PDUFA H2 2027. Fourteen months of theta. Not urgent.

Risks (ranked)

1. Approved-restricted commercial outcome (≈20%) — narrow label, REMS, BID payer friction limits launch curve. This is the short thesis and the variance we cannot rule out without HC Wainwright decode and channel work.
2. CRL on resolvable CMC issues (≈12%) — CMO-dependent manufacturing, April 2026 100% pharma tariff overhang.
3. CRL fundamental (≈8%) — safety signal in open-label extension or class-effect read-through from Sotyktu.
4. Sotyktu post-market boxed warning — would damage envu by class association.
5. Lonigutamab disposition terms below expectations — small magnitude, ≈$51M on $2.9B.

Catalysts

What would change our mind

• HC Wainwright thesis decode revealing material commercial concern → bearish update
• envu safety signal in open-label extension → exit
• Bid from ABBV/PFE/LLY/SNY/JNJ at tuck-in scale → collapses horizon, M&A premium dominates
• LUMUS SLE positive → activates SLE optionality factor (+$1-1.5B implied valuation)
• 16.2% short interest unwinding → confirms commercial bears capitulating
• Lonigutamab sold materially above $0 → small positive vs assumed-zero
• Q2 2026 ATM raise above $150M → dilution signal, trim

Evidence

Cumulative LR 49.01 (log Bayes 3.89, bullish). Predictions: NDA submission 88% by Dec 2026; FDA acceptance 92% by Feb 2027; FDA approval 80% by Dec 2027; lonigutamab impairment 72% by Aug 2026; lonigutamab disposition 70% by Dec 2026; LUMUS SLE positive 50% by Sep 2026.